A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2015
Price : $35 *
At a glance
- Drugs Flufirvitide-3 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Autoimmune Technologies
- 10 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 13 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.